Rapamycin

Expert Positions

Andrew Huberman

Explicitly Avoids It

Peter Attia

Cautiously Prescribes to Patients

Rhonda Patrick

Discusses mTOR, Not Rapamycin

Bryan Johnson

Tried and Discontinued

Mark Hyman

Mentions Favorably, No Protocol

The Verdict

Rapamycin is the most polarizing longevity intervention among the 5 experts. Attia is the most bullish, cautiously prescribing it to patients and calling it a potential 'gold standard' geroprotective molecule. Johnson experimented with it extensively but discontinued after experiencing side effects and finding a pre-print suggesting it accelerated biological aging. Huberman explicitly avoids it, citing insufficient human data. Hyman mentions it favorably as a cutting-edge longevity therapy but provides no direct protocol. Patrick discusses the mTOR pathway extensively but does not cover rapamycin as a supplement.